Prediction of sentinel lymph node positivity by growth rate of cutaneous melanoma

Archives of Dermatology

Volumn 148, Issue 5, 2012, Pages 577-584

  Tejera Vaquerizo, Antonio ^a   Nagore, Eduardo ^b   Herrera Acosta, Enrique ^a   Martorell Calatayud, Antonio ^b   Martín Cuevas, Paula ^a   Traves, Víctor ^b   Herrera Ceballos, Enrique ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRESLOW THICKNESS; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; GROWTH RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC SATELLITOSIS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SENTINEL LYMPH NODE POSITIVITY;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SPAIN; SURVIVAL RATE;

EID: 84861379095     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.2522     Document Type: Article

References (39)

1. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705-727.
2. Grob JJ, Richard MA, Gouvernet J, et al. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer. 2002;102(1):34-38.
3. Tejera-Vaquerizo A, Barrera-Vigo MV, López-Navarro N, Herrera-Ceballos E. Growth rate as a prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol. 2010;24(2):147-154.
4. Nagore E, Martorell-Calatayud A, Botella-Estrada R, Guillén C. Growth rate as an independent prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol. 2011;25(5):618-620.
5. Liu W, Dowling JP, Murray WK, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006; 142(12):1551-1558. (Pubitemid 44969210)
6. Martorell-Calatayud A, Nagore E, Botella-Estrada R, et al. Defining fast-growing melanomas: reappraisal of epidemiological, clinical, and histological features. Melanoma Res. 2011;21(2):131-138.
7. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
8. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR III, Leong SP. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol. 1998;134(8):983-987. (Pubitemid 28385320)
9. Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol. 2005;141(8):1016-1022. (Pubitemid 46165525)
10. Lowe JB, Hurst E, Moley JF, Cornelius LA. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139(5):617-621. (Pubitemid 36576377)
11. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25(7):869-875. (Pubitemid 350002888)
12. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006;107(10):2436-2445. (Pubitemid 44748527)
13. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109(1):100-108. (Pubitemid 46120199)
14. Nagore E, Botella-Estrada R, Garcia-Casado Z, et al. Comparison between familial and sporadic cutaneous melanoma in Valencia, Spain. J Eur Acad Dermatol Venereol. 2008;22(8):931-936.
15. Nagore E, Botella-Estrada R, Requena C, et al. Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site [in Spanish]. Actas Dermosifiliogr. 2009;100(3):205-211.
16. Nagore E, Pereda C, Botella-Estrada R, Requena C, Guillén C. Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control. 2009;20(1):115-119.
17. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneousmelanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97(6):1488-1498. (Pubitemid 36297779)
18. Clark WH Jr, Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893-1904. (Pubitemid 20026075)
19. Argenziano G, Kittler H, Ferrara G, et al. Slow-growing melanoma: a dermoscopy follow-up study. Br J Dermatol. 2010;162(2):267-273.
20. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220(6):759-767. (Pubitemid 24376374)
21. Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update part II. J Am Acad Dermatol. 2010;62(5):737-750.
22. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11(3):247-258. (Pubitemid 40486764)
23. Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12(4):282-288. (Pubitemid 40616492)
24. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13(4):533-541.
25. Mocellin S, Ambrosi A, Montesco MC, et al. Support vector machine learning model for the prediction of sentinel node status in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13(8):1113-1122. (Pubitemid 44337971)
26. Mandalà M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer. 2009;45(14):2537-2545.
27. Kunte C, Geimer T, Baumert J, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res. 2010;20(4):330-337.
28. Mays MP, Martin RC, Burton A, et al. Should all patients with melanoma between 1 and 2mmBreslow thickness undergo sentinel lymph node biopsy? Cancer. 2010;116(6):1535-1544.
29. Mitra A, Conway C, Walker C, et al. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer. 2010;103(8):1229-1236.
30. Roach BA, Burton AL, Mays MP, et al. Does mitotic rate predict sentinel lymph node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg. 2010;200(6):759-764.
31. Day CL Jr, Harrist TJ, Gorstein F, et al. Malignant melanoma: prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg. 1981;194(1):108-112. (Pubitemid 12197159)
32. Kimsey TF, Cohen T, Patel A, Busam KJ, Brady MS. Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol. 2009;16(5):1176-1183.
33. Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group trial E1690. J Clin Oncol. 2002;20(8):2053-2057. (Pubitemid 34408795)
34. Shaikh L, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR III, Kashani-Sabet M. The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol. 2005;141(6):739-742. (Pubitemid 41001074)
35. Lipsker D, Engel F, Cribier B, Velten M, Hedelin G. Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol. 2007;157 (2):338-343. (Pubitemid 47083865)
36. Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAF T1799A(V600E) mutation in primary melanoma. J Invest Dermatol. 2007;127(4):900-905. (Pubitemid 46434654)
37. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666- 1674.
38. Baade PD, English DR, Youl PH, McPherson M, Elwood JM, Aitken JF. The relationship between melanoma thickness and time to diagnosis in a large populationbased study. Arch Dermatol. 2006;142(11):1422-1427. (Pubitemid 44790635)
39. Liu W, McArthur GA, Trivett M, Murray WK, Wolfe R, Kelly JW. Correlation of subjective self-reported melanoma growth rate with objective tumor proliferation markers. Arch Dermatol. 2008;144(4):555-556. (Pubitemid 351581122)